期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血清HER-2DNA在乳腺癌中的诊断价值及临床意义 被引量：2

下载PDF
导出
摘要 目的检测乳腺癌患者血清人类表皮生长因子受体2（human epidermal growth factor receptor 2,HER-2）DNA的水平,探讨其诊断价值及临床意义。方法收集乳腺癌血清标本92例、乳腺良性病变血清标本37例、健康对照血清标本53例,利用实时荧光定量PCR方法检测血清HER-2 DNA水平,并分析血清HER-2 DNA与乳腺癌临床病理特征的关系及其对乳腺癌的诊断效能。结果乳腺癌组血清HER-2DNA水平[3 088.2（1 681.4~5 592.2）copies/μl]明显高于乳腺良性病变组和健康对照组（P〈0.05）;肿瘤大小、有无淋巴转移及病理学分级和TNM分期的乳腺癌患者血清HER-2 DNA水平差异有显著性（P〈0.05）;以1 675.5 copies/μl为临界值,血清HER-2诊断乳腺癌的灵敏度为72.6%,特异性为73.1%。结论血清HER-2 DNA在乳腺癌患者中明显升高,并与乳腺癌的临床特征关系密切,有望成为乳腺癌诊断的实验室指标之一。
作者 陈治水 薛成军 刘艺 袁蓉 文娟娟 王勇军 崔丽娟
机构地区 解放军第 解放军第 解放军第
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2015年第1期83-85,共3页 Chinese Journal of Clinical and Experimental Pathology
关键词 乳腺肿瘤 血清HER-2 DNA 诊断效能
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Kohler C, Radpour R, Barekati Z, et al. Levels of plasma circu- lating cell free nuclear and mitochondrial DNA as potential biemar- kers for breast tumors[ J]. Mol Cancer, 2009,8 : 105.
  • 2Page K, Hava N, Ward B, et al. Detection of HER-2 amplifica- tion in circulating free DNA in patients with breast cancer[J]. Br J Cancer, 2011,104(8) : 1342 -8.
  • 3Wolff A C, Hammond M E, Hicks D G, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast canc- er: American society of clinical oncology/college of American pa- thologists clinical practice guideline update [J]. J Clin Oncol, 2013,31 (31) : 3997 -4013.
  • 4de Abreu Pereira D, Areias V R, Franco M F, et al. Measurement.of HER-2 in saliva of women in risk of breast cancer [ J ]. Pathol Onco| Res, 2013,19(3) :509 - 13.
  • 5李峰,董赟,张宏,冯一中.乳腺癌Her-2基因扩增和蛋白表达差异及其与激素受体表达的关系[J].临床与实验病理学杂志,2013,29(9):941-945. 被引量：6
  • 6Ran N, Qin LX, Tu H, et al. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellutar carcinoma[ J]. J Cancer Rcs Clin On- col, 2006,132(6) :399 -407.
  • 7Bastian P J, Palapattu G S, Yegnasubramanian S, et al. Prognos- tic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy [ J ]. Clin Cancer Res, 2007,13 (18) :5361 - 7.
  • 8Bechmann T, Andersen R F, Pallisgaard N, et al. Plasma I-IER-2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer[J]. J Cancer Res Clin Oncol, 2013,139(6) : 995 - 1003.
  • 9Hashad D, Sorour A, Ghazal A, et al. Free circulating tumor DNA as a diagnostic marker for breast cancer [ J ]. J Clin Lab Anal, 2012,26(6) :467 -72.

二级参考文献22

  • 1孙荔,徐迎春,张凤春.乳腺癌组织雌激素和孕激素受体及c-erbB-2的表达[J].上海交通大学学报（医学版）,2007,27(6):713-715. 被引量：7
  • 2Swiatoniowski G, Dabrowska M, Klaniewski T, et al. Erb-2 over- expression in breast cancer J 1. Ginekol Pol, 2003,74 (4) : 832 -8.
  • 3李从善.一种石蜡组织芯片蜡块制作设备:中国,200920350099.2[P/OL].2010-9-15.http://www2.soopat.corn/Patent/200910265476.
  • 4Hammond M E, Hayes D F, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[ J]. J Clin Oncol, 2010, 28(16) :2784 -95.
  • 5Wolff A C, Hammond M E, Schwartz J N, et al. American Socie- ty of Clinical OncologyJCollege of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testingin breast cancer [ J . J Clin Oncol, 2007,25 ( 1 ) : 118 - 45.
  • 6Press M F, Bernstein L, Thomas P A, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas[ J]. J Clin On- col, 1997,15 ( 8 ) :2894 - 904.
  • 7Bull S B, Ozcefik H, Pinnaduwage D, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poorsurvival in node-negative breast cancer[ J]. J Clin Oneol, 2004, 22(1) :86 -96.
  • 8Piccart-Gebuart M J, Procter M, Leyland-Jones B, et al. Trastu- zumab after adjuvant chemotherapy in Her-2-positivebreast cancer [J]. N Engl J Med, 2005,353(16) :1659 -72.
  • 9Romond E H, Perez E A, Bryant J, et al. Trastuzumab plus adju- vant chemotherapy for operable Her-2-positive breast eaneer[ J ]. N Engl J Med, 2005,353 (16) : 1673 - 84.
  • 10Smith I, Procter M, Gelber R D, et al. 2-year follow-up of trastu- zumab after adjuvant chemotherapy in Her-2-positive breast canc- er: a randomised controlled trial[J]. Lancet, 2007,369(9555) : 29 - 36.

共引文献5

同被引文献17

引证文献2

二级引证文献7

临床与实验病理学杂志
2015年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部